NCT03874806

Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block

Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block: a Comparison of Bolus Dosing and Continuous Infusion

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Virginia Commonwealth University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goals of this study are as follows: 1. to confirm the safe dosing of ropivacaine for the erector spinae plane block 2. develop a pharmacokinetic profile of the erector spinae plane block, which will help demonstrate how quickly and how closely toxic levels are reached when a routine dose of ropivacaine is given for this nerve block 3. assess numbness created by the erector spinae block when routine doses are administered

Conditions

• Pain, Postoperative
• Pain, Chest

Interventions

Type	Name	Description
DRUG	Ropivacaine 0.25%-NaCl 0.9% Injectable Solution	0.25% ropivacaine administered through a nerve catheter
DRUG	Ropivacaine 0.2%-NaCl 0.9% Injectable Solution	0.2% ropivacaine administered through a nerve catheter

Timeline

• Start date: 2019-07-01
• Primary completion: 2020-07-01
• Completion: 2020-12-31
• First posted: 2019-03-14
• Last updated: 2019-07-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study